Oncotarget Authority Increases With A Higher Impact Rating

Recently Oncotarget announced that their new impact factor is 5.168. The number of times the average article, published in the last two years, is cited in a journal determines the impact factor; Oncotarget’s articles were cited 30,241 times in 2016. Important journals typically have higher impact factors than less important journals.In the 2015-2016 time period, Oncotarget had more articles published than any other oncology journal, with significantly more than the second place journal.Oncotarget is a peer-reviewed medical journal published weekly.

The focus is on cancer research, tumor development, treatment protocols and everything related to cancer. Oncotarget also publishes papers covering age-related diseases, immunology and pathology. Research papers are published quickly, as long as they meet Oncotarget’s requirements and pass the peer review process. Approved papers appear online in as little as five days.Papers published by Oncotarget are open access, published under a Creative Commons Attribution 3.0 License.

Authors retain the copyright, however, the journal is available online for anyone to read. People may also use or reprint the article as long as they give credit to the authors and Oncotarget. While Oncotarget’s articles are reprinted by websites that aggregate research papers, other articles, such as a recent article that claims leukemia may be halted by Vitamin C, are interesting to the public as well as other cancer researchers.Mikhail V. Blagosklonny and Andrei V. Gudkov of the Roswell Park Cancer Institute are the journal’s editors-in-chief. The founding editorial board consists of prominent individuals from Harvard, Johns Hopkins University and cancer research centers.